Effects of I125 seed stent implantation combined with arterial infusion chemoembolization on tumor markers, p53 expression, and prognosis in patients with cholangiocarcinoma

Figures & data

Table 1. Patient details

Basic information	Group A	Group B	χ^2	P
Gender			0.217	0.641
male	25(64.10%)	23(58.97%)
female	14(35.90%)	16(41.03%)
age/year			1.902	0.386
<40	3(7.69%)	5(12.82%)
40–70	28(71.79%)	30(76.92%)
>70	8(20.51%)	4(10.26%)
transfer			1.169	0.279
Intrahepatic	17(43.59%)	11(28.21%)
Extrahepatic	8(20.51%)	10(25.64%)
Cholangiocarcinoma			0.889	0.641
StageI	10(25.64%)	8(20.51%)
StageII	22(56.41%)	26(66.67%)
Stage III	7(17.95%)	5(12.82%)

Table 2. Bilirubin changes before and after treatment

bilirubin	Group A	Group B	t	p
Before treatment	236.16 Voxel changes compared to	237.19 Voxel changes compared to	1.013	0.314
3 months after treatment	50.13 The vegan variation profile ^a	31.04 The vegan variation profile ^a	0.724	0.003
6 months after treatment	29.15 The vegan variation profile ^ab	28.49 The vegan variation profile ^ab	0.296	0.801
12 months after treatment	30.99 The vegan variation profile ^ab	28.81 The vegan variation profile ^ab	0.314	0.720

Table 3. Changes in tumor size (mm2) between the two groups

Tumor size	Group A mm^2	Group B mm^2	t	P
Before treatment	1567 Tumor size	1563 Tumor size	0.017	0.979
3 months after treatment	1293 ± 293	11,629 Tumor size	0.848	0.397
6 months after treatment	14,677 Tumor size ^a	13,567 Tumor size	2.677	0.008
12 months after treatment	15,828 Tumor size ^ab	14,358 Tumor size	3.503	<0.001

Tumor size: longest diameter × widest diameter/ mm². a means pP<0.05 compared with before treatment, and b means pP<0.05 compared with 3 months after treatment.

Figure 1. Comparison of biliary patency time after treatment between the two groups of patients.

a: p < 0.05 vs. Group A.

Table 4. The expression of tumor markers in stage I-stage patients before treatment

Cholangiocarcinoma staging	CA19-9(U/mL)	CA242(U/mL)	CEA(U/mL)
stageI	462.439 In direct proportion,	58.9739 In direct proportion,	42.1439 In direct proportion.15
stageII	594.729 In direct proportion, ^a	65.1329.1^a	57.0329 In direct proportion.15^a
stageIII	779.399 In direct proportion, ^ab	77.1199.15^ab	68.9999 In direct proportion.15^ab

CA19-9: Carbohydrate Antigen 19–9, Carbohydrate Antigen 19–9; CA242: Carbohydrate Antigen242; CEA: Carcinoembryonic antigen. A represents P < 0.05 compared to pretreatment and B represents P < 0.05 compared to 3 months after treatment.

Table 5. Comparison of tumor marker expression after treatment between the two groups

Tumor markers	Group A	Group B	t	P
Before treatment
CA19-9(U/mL)	608.27 Tumor markers	614.47 Post tumor markers	0.029	0.864
CA242(U/mL)	65.887 Tumor markers	67.127 Post tumor markers	0.035	0.862
CEA(U/mL	56.037 Tumor markers	58.127 Post tumor markers	0.042	0.713
3 months after treatment
CA19-9(U/mL)	390.24 Tumor markers ^a	293.42 Tumor markers ^a	1.412	0.001
CA242(U/mL)	42.1442 Tumor markers ^a	36.9642 Tumor markers ^a	0.915	0.049
CEA(U/mL	40.222Tumor markers ^a	37.022 Tumor markers^a	1.015	0.036
6 months after treatment
CA19-9(U/mL)	486.15 Tumor markers ^ab	328.11 Tumor markers ^ab	0.921	0.041
CA242(U/mL)	53.6911 Tumor markers ^ab	45.7511 Tumor markers ^ab	0.885	0.062
CEA(U/mL	49.2311Tumor markers ^ab	41.1911 Tumor markers^ab	0.912	0.049
12 months after treatment
CA19-9(U/mL)	584.46Tumor markers ^bc	512.43 Tumor markers ^abc	1.031	0.031
CA242(U/mL)	67.2443Tumor markers ^bc	54.1743 Tumor markers ^abc	0.972	0.211
CEA(U/mL	55.3243Tumor markers ^bc	49.7243 Tumor markers ^abc	0.865	0.082

Table 6. Comparison of p53 expression after treatment between the two groups

P53	Group A	Group B	t	P
Before treatment	1.75 Posttreatment, pretreatment	1.78 Posttreatment, pretreatment	0.638	0.913
3 months after treatment	1.233 Posttreatment, pretreatment ^a	0.813 Posttreatment, pretreatment ^a	7.152	0.026
6 months after treatment	1.676 Posttreatment, pretreatment ^b	1.216 Posttreatment, pretreatment ^ab	8.511	0.018
12 months after treatment	1.798 Posttreatment, pretreatment ^b	1.358 Posttreatment, pretreatment ^ab	6.152	0.046

Figure 2. Patient survival in the two groups.